Background-The feasibility of using health system data to estimate prevalence of chronic kidney disease (CKD) stages 3-5 was explored.
patients from the US Department of Veterans Affairs (VA) health care system and a regional managed care plan, and compared the results obtained with NHANES-derived estimates of prevalence in those populations.
METHODS

Data Sources/Study Participants
National Health and Nutrition Examination Survey-The NHANES program has been well described previously. 7 Data used for this report were from the 2005-2006 survey and included information from participants 20 years or older. By design, all participants received testing for serum creatinine. Participants with missing data for serum creatinine (n = 270), who had received dialysis within 12 months of the survey (n = 16), or who were pregnant or menstruating at the time of examination (n = 440) were excluded. All analyses incorporated examination weights, strata, and pseudostrata to reflect the survey sample design.
VA Health System-The Veterans Health Administration is the largest integrated health care system in the United States. National data for VA patients are processed at the Austin Automation Center, Austin, TX, which abstracts information from VA facilities such as patient demographics, medical diagnoses and procedures, outpatient and inpatient visits, and vital status. 8 The data files include the Medical SAS Datasets, which contain information for diagnoses and procedures using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Current Procedural Terminology coding systems. In addition, the VA Decision Support System files include pharmacy information and selected laboratory results. For this study, a 5% random sample of national VA data from fiscal year 2005 was extracted. Although a linkage with VA data and Medicare claims is available, this was not used for this study to avoid limiting the population to older patients. For comparability with NHANES data, patients 20 years and older were included in the analyses, and patients with diagnosis or procedure codes indicating pregnancy, dialysis, or kidney transplantation were excluded. To ensure that patients were using the VA health care system, the cohort was limited further to individuals who had at least one outpatient visit to a VA facility in 2005.
M-CARE-M-CARE was a managed care health plan in the Southeast Michigan region that was owned and operated by the University of Michigan Health System until December 31, 2006. M-CARE created and maintained a high-quality claims data repository that describes health care utilization since 1997 for its covered population. The database includes billing claims with diagnosis and procedure codes using the ICD-9-CM and Current Procedural Terminology systems, pharmacy data files, and laboratory results in a subset of patients. For comparability to the NHANES and VA health care system data sets, data from calendar year 2005 were used, patients 20 years and older with at least one claim for an outpatient visit were selected, and those with diagnosis codes indicating dialysis, kidney transplantation, or pregnancy were excluded. A substantial proportion (49.7%) of patients had missing laboratory data (ie, a claim was present for serum creatinine testing, but no result was available). In the subset of patients who had a University of Michigan primary care physician (UM-PCP), laboratory data were available more consistently (75% of cases with a claim for serum creatinine testing had a laboratory result). Results for M-CARE data were stratified accordingly by whether patients had a UM-PCP; characteristics of the groups were compared.
Definitions of Study Variables
Detailed descriptions for selected study variables are listed in Table S1 (provided as online supplementary material). The CKD Epidemiology Collaboration (CKD-EPI) creatinine equation was used for calculation of estimated glomerular filtration rate (eGFR; for comparison, results using the 4-variable Modification of Diet in Renal Disease Study equation are listed in Table S2 ). 9 For this study, CKD then was defined as eGFR <60 mL/min/1.73 m 2 (ie, National Kidney Foundation-Kidney Disease Outcomes Quality Initiative [NKF-KDOQI] 10 stages 3-5), excluding patients on dialysis therapy or after kidney transplantation. No attempt was made to identify CKD stages 1 or 2 because urine protein assessments were available infrequently in the VA and M-CARE data sets. For the VA and M-CARE data sets, only outpatient serum creatinine values were used to minimize misclassification of episodes of acute kidney injury as CKD. If multiple serum creatinine values were available in a year, a single value was randomly chosen. In the VA or M-CARE data only, CKD also was identified separately based on the presence of at least one inpatient or outpatient ICD-9-CM diagnosis code (see Table S1 ). The CKD diagnosis codes were selected based on previous literature and study team consensus. 11, 12 Relevant comorbid conditions identified in the data sets included diabetes mellitus, hypertension, and anemia. Race was classified in NHANES as non-Hispanic white, nonHispanic black, Mexican American, other Hispanic, and other. Although the National Center for Health Statistics recommends keeping the Hispanic categories separate, the other Hispanic and Mexican American categories were grouped together as Hispanic solely for purposes of comparisons with the VA data set. In the VA data set, race was classified as non-Hispanic white, non-Hispanic black, Hispanic, Asian, Pacific Islander, Native American, and other or unknown, with the latter 5 categories grouped under the heading other/unknown. Race was unavailable in the M-CARE database.
Statistical Analyses
Demographic information for each of the data sets was tabulated. The proportion of patients undergoing testing for serum creatinine within a year in the VA and M-CARE health care systems was estimated based on the availability of an actual laboratory result and/or the presence of an outpatient claim indicating serum creatinine testing.
The prevalence of CKD stages 3-5 was calculated in NHANES data with adjustment for sampling weights and the survey design. Prevalence of CKD From Health System Data In the case of VA and M-CARE data, observed prevalence was calculated as follows: the number of persons with CKD stages 3-5 divided by the number of persons within the health care system 20 years and older who had at least one outpatient visit during the 1-year study period. For the VA and M-CARE data sets, the prevalence of CKD based on claims alone or a combination of claims and eGFR also was calculated.
When race information was missing for the VA and M-CARE data sets, eGFR was calculated using non-Hispanic white race as the default. To improve prevalence estimates when race information was missing, eGFRs also were calculated using a single imputation for black race based on the proportion of blacks in the zip code of residence of the patient (from the US Census 7 ) as follows: the race coefficient in the CKD-EPI equation was calculated as 1 + (0.159 × proportion of blacks in zip code). To assess the validity of the imputation, a comparison was made between true CKD status (ie, eGFR ≥60 or <60 mL/min/1.73 m 2 ) and CKD status imputed by zip code-based race coefficient in the group of patients with known race. The κ statistic for the comparison was 0.99, suggesting excellent agreement between classifications of CKD based on actual race versus race from the zip code imputation.
Because the observed prevalence estimates in the health care systems were expected to be underestimates due to incomplete testing for serum creatinine, a logistic regression model was fitted using the NHANES data set to predict the presence of CKD stages 3-5 based on age, race (non-Hispanic black vs nonblack), diabetes mellitus, hypertension, anemia, and sex. The coefficients from this model then were applied to the subgroups of patients who did not undergo testing for serum creatinine within the VA and M-CARE data sets to produce estimates of the predicted prevalence of CKD stages 3-5 within the untested populations. These were combined with the observed prevalence estimates based on the tested populations to produce overall estimates of the predicted prevalence of CKD stages 3-5 within the VA and M-CARE health care systems. To assess how well the model predicted CKD stages 3-5 within these health care systems, it also was applied to the subgroup that had undergone testing for serum creatinine in order to compare the predicted prevalence of CKD with the actual observed prevalence of CKD. Within NHANES data, the C statistic for the model was 0.92, with C statistics of 0.81 and 0.87 in the VA and M-CARE populations, respectively. Observed versus predicted prevalence in the tested VA and M-CARE populations across the full strata of patient clinical and demographic characteristics is listed in Table S3 .
Because the VA data set contained a substantial proportion of patients with multiple serum creatinine values within a year, the stability of the CKD stage classification based on eGFR estimation was examined. Patients in the VA system with 2 available serum creatinine measurements 3-6 months apart were selected. CKD stage classification based on eGFR at the first measurement was cross-tabulated with CKD stage classification at the second measurement to determine the proportion of patients for whom CKD stage classification remained stable.
All analyses were performed with SAS, version 9.2 (SAS Institute Inc). The study protocol was approved by the institutional review boards of the University of Michigan and VA Ann Arbor Healthcare System. Table 1 presents a comparison of population characteristics across the NHANES (ie, general United States), VA, and M-CARE data sets. Compared to the NHANES population, the VA system included a predominantly male, older population with a higher prevalence of comorbid conditions, such as diabetes mellitus and hypertension. The M-CARE population included a generally younger, healthier population.
RESULTS
Comparison of Population Characteristics
Proportion of Patients Tested
The proportion of patients tested for serum creatinine was significantly higher in the VA system (75.8%) than in the M-CARE UM-PCP (36.6%) or non-UM-PCP (41.3%) populations (Table 2 ). In both the VA and M-CARE populations, testing increased with age and was higher in patients with diabetes mellitus or hypertension, with persisting differences between the VA and M-CARE systems. The proportion tested for albuminuria was very low regardless of health care system; 10.3% had measured albuminuria in the VA system (35.6% with diabetes and 14.1% with hypertension) and 6.0% had albuminuria measurement in the overall M-CARE population (45.2% in patients with diabetes and 17.1% in patients with hypertension). Table 3 lists observed estimates of the prevalence of CKD stages 3-5 in the NHANES, VA, and M-CARE (including only the subset with a UM-PCP) data sets. Observed prevalence was highest in the VA, intermediate in NHANES, and lowest in the M-CARE system. In all 3 data sets, prevalence was higher with increasing age, presence of diabetes mellitus, and presence of hypertension. Imputation of race in the M-CARE and VA data sets led to a small reduction in the estimated prevalence of CKD stages 3-5 (ie, an increase in population mean eGFR) in the VA system only compared to the assumption that all patients with unknown race were white. CKD prevalence based on ICD-9-CM diagnosis claims alone produced substantially lower estimates than those based on eGFR calculation. A definition of CKD based on eGFR and/or diagnosis claims produced prevalence estimates slightly higher than for eGFR alone for both the VA and M-CARE data sets. Figure 1 shows results for the VA and M-CARE health systems comparing the observed prevalence of CKD stages 3-5 versus the prevalence predicted based on a model using NHANES data. To evaluate how well the model predicted CKD stages 3-5 in the health care systems, the predicted and observed prevalences of CKD stages 3-5 initially were compared using only patients who had undergone testing for serum creatinine (Fig 1, left  panel) . The 2 estimates were virtually identical for the M-CARE data, but the predicted prevalence of CKD stages 3-5 was slightly higher than the observed prevalence within the VA data. There were substantial gaps in both the VA and M-CARE systems between observed and predicted prevalences in the overall population (Fig 1, right panel) , with the observed prevalence being roughly two-thirds of the predicted prevalence. Table 4 presents the stability of CKD staging by eGFR in the VA system among the subset of individuals who had 2 serum creatinine results available 3-6 months apart (n = 26,080; mean age, 66.1 years; diabetes, 39.6%; and hypertension, 83.0%). In those with an initial eGFR >60 mL/min/1.73 m 2 , >90% remained stable. For those with CKD stages 3-5 at initial assessment, two-thirds to three-quarters remained within the same classification at assessment 3-6 months later. In most cases in which stage classification was different, individuals were classified into a less severe stage (ie, with a higher eGFR). For example, in those initially classified with stage 3 CKD, 20% were classified as not having CKD on the basis of subsequent serum creatinine-based eGFR calculation.
Estimated CKD Stages 3-5 Prevalence in VA and M-CARE Systems
Stability of CKD Staging
DISCUSSION
This study assessed the feasibility of producing estimates of CKD prevalence using available data from a large national and a large regional health care system. A number of potential issues and challenges were identified. One major issue was the choice of denominator for the calculation of prevalence. In NHANES, all participants undergo testing for serum creatinine by design, allowing estimation of the "true prevalence" of CKD within the population. The numerator of the prevalence calculation includes persons with CKD and the denominator is simply the entire survey population (using appropriate survey weights when estimating national prevalence). When using health care system data, estimating prevalence is more complex because testing for serum creatinine generally is performed only for clinical indications. Using a denominator that includes only those tested, as some studies have done, 13, 14 therefore would tend to overestimate the true prevalence of CKD. We instead chose to use a denominator that included the entire population available (with noted exclusions) in the health care data set. However, the extent to which this prevalence approximates the "true prevalence" will depend on testing practices. In an idealized scenario, if untested persons were uniformly free of CKD, the prevalence of CKD as observed in the health care system data would equal the true prevalence of CKD in the population under consideration. To the extent that some persons with CKD are not tested, the prevalence based on health care system data would be an underestimate of the true prevalence. We used modeling based on NHANES data to assess the degree to which this underestimation occurred by examining the predicted prevalence of CKD in the untested populations of the health care systems. In the context of this study, the observed prevalence of CKD stages 3-5 in the total population was a third lower than the predicted prevalence (Fig 1) , even within the VA system with its robust electronic health record and implementation of clinical reminders. 15 This highlights the ongoing need to optimize strategies for appropriate testing and identification of persons with CKD in both the general population and high-risk groups.
Another important issue is the availability of laboratory data within the health care system for calculation of eGFR. Previous studies have shown that diagnosis claims for CKD, although relatively specific, have poor sensitivity for the presence of CKD, potentially leading to substantial underestimation of prevalence. 12, 13 In this study, prevalence estimates for CKD based on diagnosis claims alone were 60% lower than those based on eGFR in the VA and M-CARE systems. Even when laboratory results generally are available in the health care system, issues with missing values can exist, as we noted in this study within the M-CARE system. Although we were able to identify a subset of patients (with UM-PCPs) who more consistently had laboratory results available, the data were still incomplete, and this likely also contributed to the large gap in observed versus predicted prevalence within the M-CARE system. Finally, error also could be introduced from variations in assays and lack of standardization for measurement of serum creatinine across laboratories used by health care systems. 16 The quality of the data for patient characteristics relevant to CKD also is important. Missing information for race is a frequent issue in health care system data because it often is not routinely or accurately collected. We used a method to impute race from census data on the proportion of blacks within the zip code of the patient's residence, similar to what others have done previously. 17 This method produces results that are reasonably consistent with those based on actual patient-level race information. Comparisons across health care systems or with NHANES data also require accurate information for comorbid conditions to adequately adjust for differences in population characteristics that may influence the prevalence of CKD. Even when some information for comorbid conditions is available, it may not be easily comparable across health care systems or compared with NHANES data. In the context of this study, for example, the presence of diabetes mellitus was necessarily defined differently in NHANES versus M-CARE or VA data (see Table S1 ). As a result, inadequate adjustment for comorbid conditions could have led to errors in estimation of the predicted prevalence of CKD.
A final important point relates to the stability of eGFR assessments and the definition of CKD. The formal definition of CKD requires a reduced GFR for at least 3 months, although this often is not strictly followed, such as with NHANES data, which includes only one measurement of serum creatinine. 18 When we examined this issue in the VA data, we found that for patients with at least 2 serum creatinine measurements 3-6 months apart, nearly 20% initially identified as stage 3 CKD by eGFR would no longer be classified as having CKD based on their second measurement. However, the absolute change in eGFR between the 2 assessments was relatively modest (median difference, 6.5 mL/min/1.73 m 2 ) and likely of minimal clinical significance, with the change in classification occurring predominantly in patients with eGFRs close to the top of the range of their initial CKD stage. Furthermore, restricting the sample of patients to those with at least 2 serum creatinine measurements introduces a substantial selection bias, tending to include a sicker population of patients. As such, it probably is reasonable to base estimates of CKD prevalence in the health care system on a single outpatient measurement of serum creatinine. However, users of the data should be made aware that the estimates do not meet the strict requirement of chronicity.
In summary, estimation of the prevalence of CKD within health care systems, although feasible in principle, remains a challenge due to issues related to the definition of the denominator and, in particular, the quality of the data. With the recent legislated emphasis on electronic health records, the availability of data relevant to these efforts is likely to expand in coming years. Our findings suggest that important areas for improvement for electronic health care data include: ensuring the availability and completeness of laboratory results, collecting detailed information for race, and developing consistent definitions for recording comorbid conditions. Nevertheless, health care system data in its present state can be useful for surveillance relevant to the care of CKD. Within health care systems with relatively complete laboratory data, such as in the VA system, we have shown that it is possible to derive estimates of prevalence, supplemented with data from NHANES. With appropriate analysis and inference, this could be used by health care systems to track the burden of CKD within the covered populations over time, to implement disease management strategies, or to help assess the potential impact of interventions directed at preventing or treating CKD. It also is possible to estimate the magnitude of and trends in potential gaps in testing practices for CKD by comparing observed prevalence to predicted estimates based on adjusted NHANES data, which can be used by health care systems to direct and monitor quality improvement efforts. Observed versus predicted prevalence of chronic kidney disease (CKD) stages 3-5 in the M-CARE and Veterans Affairs (VA) health care systems. Predicted prevalence was derived from a logistic regression model fitted using the National Health and Nutrition Examination Survey (NHANES) 2005-2006 data set to predict the presence of CKD stages 3-5 based on age, race (non-Hispanic black vs nonblack), diabetes mellitus, hypertension, anemia, and sex. The coefficients from this model were used to produce estimates of the prevalence of CKD within the VA and M-CARE cohorts based on the respective characteristics of those populations. Observed and predicted prevalence are shown for both the population tested for serum creatinine (Tested Population) and those not tested (Untested Population). The predicted prevalence presented for the total population is a combination of the observed prevalence in the tested population and the prevalence in the untested population based on the NHANES model. The vertical thin bars represent 95% confidence intervals. For the overall prevalence calculation, all patients with missing race were assumed to be non-Hispanic white. The overall (missing race imputed) prevalence was calculated using race imputation based on zip code, as described in the Methods section. c There were 6,146 patients with missing zip code information and who therefore were assumed to be white for the purposes of the eGFR calculation.
d Estimate omitted due to low sample size.
e The National Center for Health Statistics recommends keeping Mexican American Hispanic and other Hispanic categories separate for reporting purposes for surveys prior to 2007, but these categories were collapsed for comparability to the VA data set.
